Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
MedBiome
MedBiome develops precision microbiome therapeutic and nutritional products to improve human health. MedBiome has a novel platform to screen compounds for their effects on living human microbiomes in 96 well plates. We use this technology for: 1) the development of precision microbiome nutritional and therapeutics products targeting specific microbiome metabolites with a focus on pediatric IBD and new programs in gut-brain axis, and Chronic Kidney Disease. 2) partnering with biotechnology and pharmaceutical companies seeking to screen their proprietary drugs, nutritional compounds, natural compounds, and other compounds against panels of human/animal microbiomes.
Presenter: Daniel Figeys, President
Read More
Morphocell Technologies
Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its allogeneic stem cell-derived engineered liver tissues (ELT). Its mission is to transform the treatment of liver disease by the means of cell therapy. With $2.1M in pre-seed funding, we significantly de-risked the technology, collected compelling efficacy/safety data and addressed key scalability hurdles in manufacturing. We are seeking $4.5M to confirm the efficacy and safety of the ELT in large animals. Achieving this key value inflection point would trigger a larger series A investment from already engaged parties, thus enabling pre-clinical development up to CTA/IND application.
Presenter: Massimiliano Paganelli, Co-founder and CEO
Read More
Oncoustics
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Oncoustics applies AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics is a clinical-stage company with partnerships with several ultrasound OEMs, and FDA pre-sub and trials this year. Oncoustics is raising Series A capital to bring the first product to market (FDA clearance), and continue growing the data library for new indications, as well as grow the team.
Presenter: Ahmed El Kaffas, Founder
Read More
